CN104523861A - Traditional Chinese medicine combination used for treating stroke and preparation method thereof - Google Patents
Traditional Chinese medicine combination used for treating stroke and preparation method thereof Download PDFInfo
- Publication number
- CN104523861A CN104523861A CN201410853808.4A CN201410853808A CN104523861A CN 104523861 A CN104523861 A CN 104523861A CN 201410853808 A CN201410853808 A CN 201410853808A CN 104523861 A CN104523861 A CN 104523861A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- radix
- parts
- apoplexy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention belongs to the technical field of traditional Chinese medicine, particularly discloses a traditional Chinese medicine combination used for treating stroke and further discloses a preparation method of the traditional Chinese medicine combination. The traditional Chinese medicine combination used for treating stroke is composed of, by weight, 90-110 parts of red ginseng, 190-210 parts of red sage roots, 90-110 parts of pseudo-ginseng, 40-60 parts of ground beetles, 90-110 parts of pangolins, 40-60 parts of leeches and 50-70 parts of Chinese teasel roots. The traditional Chinese medicine combination is concise in formula and definite in compatibility; the seven types of medicine are used at the same time, so the effects of cultivating the root, solidifying the vitality, supplementing qi, restoring the pulse, removing blood stasis and dredging collaterals can be achieved. The traditional Chinese medicine combination has a unique treatment effect on ischemic stroke especially muscle strength decrease and muscular tension increase caused by ischemic stroke.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition being used for the treatment of apoplexy, also relate to its preparation method simultaneously.
Background technology
Apoplexy is a kind of disease being main clinical manifestation with cerebral ischemic and heamorrhagic lesions symptom, also known as apoplexy or cerebrovas-cularaccident, there is high case fatality rate and disability rate, be mainly divided into hemorrhagic cerebral apoplexy and the large class of ischemia apoplexy two, the most common with cerebral infarction.The essence of apoplexy is the neck arteries generation pathological changes of brain tremulous pulse or domination brain, causes focal disturbance of blood circulation, and then the acute or subacute cerebral lesion caused.Modal symptom is exactly that language that degree is different, motion, sensory disturbance appear in patient, is referred to as hemiplegia, is commonly called as " hemiplegia " with dyskinesia for main person's traditional Chinese medical science.Apoplexy belongs to one of common clinical, frequently-occurring disease, is generally more common in middle-aged and elderly people, and its sickness rate, disability rate and case fatality rate remain high at present, and occurs the trend of age of onset rejuvenation.
Though the clinical Chinese medicine preparation being used for the treatment of apoplexy is many at present, due to many limitations of the principles of formulating prescriptions, dosage form and clinical efficacy aspect, its scope of application is still restricted.Therefore, Chinese medicine preparation evident in efficacy, easy to use is developed still by Stroke Management Treatment is badly in need of.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition being used for the treatment of apoplexy, the merit of reinforcing primordial QI reinforcing, Yiqi and vein recovery, removing blood stasis dredging collateral can be reached, to ischemia apoplexy determined curative effect.
The present invention also aims to provide a kind of preparation method being used for the treatment of the Chinese medicine composition of apoplexy.
In order to realize above object, the technical solution adopted in the present invention is: a kind of Chinese medicine composition being used for the treatment of apoplexy, is made up of the crude drug of following parts by weight:
Radix Ginseng Rubra 90-110 part
Radix Salviae Miltiorrhizae 190-210 part
Radix Notoginseng 90-110 part
Eupolyphaga Seu Steleophaga 40-60 part
Squama Manis 90-110 part
Hirudo 40-60 part
Radix Et Rhizoma Rhei 50-70 part.
Preferably, described Chinese medicine composition is capsule or tablet or granule.
Be used for the treatment of a preparation method for the Chinese medicine composition of apoplexy, comprise the following steps:
(1) each crude drug is taken by following parts by weight: Radix Ginseng Rubra 90-110 part, Radix Salviae Miltiorrhizae 190-210 part, Radix Notoginseng 90-110 part, Eupolyphaga Seu Steleophaga 40-60 part, Squama Manis 90-110 part, Hirudo 40-60 part, Radix Et Rhizoma Rhei 50-70 part;
(2) get Radix Ginseng Rubra, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo, be ground into fine powder, for subsequent use;
(3) get Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, add alcohol reflux 2 times, boil at every turn and carry 1.5 hours, merge extractive liquid, filter, gained filtrate reduced in volume reclaims ethanol, and filtrate concentrating obtains the alcohol extraction clear paste (60 DEG C of heat are surveyed) that relative density is 1.25;
The filtration residue of alcohol extraction adds water and decocts 2 times again, each 1.5 hours, collecting decoction, filters, and filtrate reduced in volume obtains the water extraction clear paste (60 DEG C of heat are surveyed) that relative density is 1.25;
The alcohol extraction clear paste obtained and water extraction clear paste are merged, mixing, obtained clear paste, for subsequent use;
(4) clear paste that fine powder step (2) obtained and step (3) obtain mixes, and dries, then is ground into fine powder, make granule, incapsulate, obtain the Chinese medicine composition being used for the treatment of apoplexy.The content of capsule is red-brown powder, gas raw meat, mildly bitter flavor.
Wherein, in step (3), when adding alcohol reflux, the consumption of ethanol is: the weight of ethanol: gross weight=6 of Radix Salviae Miltiorrhizae and Radix Et Rhizoma Rhei.
In step (3), when adding alcohol reflux, ethanol used to be mass percent concentration be 80% ethanol.
Be used for the treatment of in the Chinese medicine composition of apoplexy provided by the invention, Radix Ginseng Rubra matter is hard, body weight and crisp, gas is fragrant, and mildly bitter flavor is the cooked of Radix Ginseng, its property of medicine is warmer, has the advantages that fire is large, strength is sufficient, effect is strong, is more longer than strongly invigorating primordial QI, recuperating depleted YANG and rescuing the patient from collapse, nourishing qi to stop; Radix Salviae Miltiorrhizae, bitter, be slightly cold, GUIXIN, pericardium, Liver Channel, promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, relieving restlessness are calmed the nerves, and reuse Radix Salviae Miltiorrhizae in this Chinese medicine composition, can strengthen the effect of its blood circulation promoting and blood stasis dispelling; Radix Notoginseng, has another name called Radix Notoginseng, sweet, micro-hardship, and temperature, returns liver, stomach warp, removing stasis to stop bleeding, analgesic therapy of invigorating blood circulation; " three ginseng " Radix Ginseng Rubra, Radix Salviae Miltiorrhizae, Radix Notoginseng are rationally composite, and be monarch drug altogether, it not only has joins the element culturing fixed folder of class medicine, the merit of Yiqi and vein recovery, more has the effect of activating blood circulation to dissipate blood stasis and dredge the collateral; Eupolyphaga Seu Steleophaga, salty, cold, return Liver Channel, removing blood stasis, reunion of fractured tendons and bones; Squama Manis, salty, be slightly cold, return liver, stomach warp, the Xiao Disorder that invigorates blood circulation, stimulate the menstrual flow, stimulating milk secretion, detumescence and apocenosis; Hirudo, salty, bitter, flat, return Liver Channel, removing blood stasis stimulates the menstrual flow, Zhu Yu Xiao Disorder; It is ministerial drug altogether that Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo three share, and has the property of walking to alter, and can have removing blood stasis, a merit of stimulating the menstrual flow, auxiliary " three ginsengs ", to strengthen the power of the invigorating blood circulation of Chinese medicine composition, removing blood stasis, removing blood stasis, the meridian dredging; Radix Et Rhizoma Rhei, bitter, cold, return spleen, stomach, large intestine, liver, pericardium channel, heat and toxic materials clearing away, clearing away heat-fire, removing pathogenic heat from blood and toxic substance from the body, eliminating blood stasis and inducing menstruation; In the Chinese medicine composition of the application, Radix Et Rhizoma Rhei is adjuvant, and one is, by the property of its bitter cold with the power of the system of helping " three ginsengs " tonification, in case too; Two are, use the D score method in " antiperspirant, tell, under " three methods, pathogenic heat are gone from stool, makes body equilibrium between yin and yang; Three are, because it has the merit of eliminating blood stasis and inducing menstruation, assistant helps other Six-element medicines, to play larger effect; Four are, lead the efficacy of a drug of all the other Six-element medicines to arrive spleen, stomach, large intestine, liver, pericardium channel.Clearly, seven flavor medicine is same by the merit that can reach reinforcing primordial QI reinforcing, Yiqi and vein recovery, removing blood stasis dredging collateral for the refine of the application's Traditional Chinese medicine composition formula, compatibility, for the cerebral infarction curative effect that muscular strength reduces, hypermyotonia has uniqueness that particularly cerebral infarction causes.
Detailed description of the invention
Below by specific embodiment, technical scheme of the present invention is described in detail.
Embodiment 1
Be used for the treatment of a Chinese medicine composition for apoplexy, be made up of the crude drug of following parts by weight:
Radix Ginseng Rubra 90 parts
Radix Salviae Miltiorrhizae 210 parts
Radix Notoginseng 90 parts
Eupolyphaga Seu Steleophaga 40 parts
Squama Manis 110 parts
Hirudo 40 parts
Radix Et Rhizoma Rhei 50 parts.
This is used for the treatment of the preparation method of the Chinese medicinal composition capsules agent of apoplexy, comprises the following steps:
(1) each crude drug is taken by following parts by weight: Radix Ginseng Rubra 90 parts, Radix Salviae Miltiorrhizae 210 parts, Radix Notoginseng 90 parts, Eupolyphaga Seu Steleophaga 40 parts, Squama Manis 110 parts, Hirudo 40 parts, Radix Et Rhizoma Rhei 50 parts;
(2) get Radix Ginseng Rubra, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo, be ground into fine powder, for subsequent use;
(3) Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei is got, add alcohol reflux 2 times, the consumption of ethanol is: the weight of ethanol: gross weight=6 of Radix Salviae Miltiorrhizae and Radix Et Rhizoma Rhei, ethanol used to be mass percent concentration be 80% ethanol, boil at every turn and carry 1.5 hours, merge extractive liquid, filter, gained filtrate reduced in volume reclaims ethanol, and filtrate concentrating obtains the alcohol extraction clear paste that relative density is 1.25;
Alcohol extraction filtration residue adds water and decocts 2 times again, each 1.5 hours, collecting decoction, and filter, filtrate reduced in volume obtains the water extraction clear paste that relative density is 1.25;
Alcohol extraction clear paste and water extraction clear paste are merged, mixing, obtained clear paste, for subsequent use;
(4) clear paste that fine powder step (2) obtained and step (3) obtain mixes, and dries, then is ground into fine powder, make granule, incapsulate, obtain the capsule of the Chinese medicine composition being used for the treatment of apoplexy, its content is red-brown powder, gas raw meat, mildly bitter flavor.
Embodiment 2
Be used for the treatment of a Chinese medicine composition for apoplexy, be made up of the crude drug of following parts by weight:
Radix Ginseng Rubra 110 parts
Radix Salviae Miltiorrhizae 190 parts
Radix Notoginseng 110 parts
Eupolyphaga Seu Steleophaga 60 parts
Squama Manis 90 parts
Hirudo 60 parts
Radix Et Rhizoma Rhei 70 parts.
This is used for the treatment of the preparation method of the Chinese medicinal composition capsules agent of apoplexy, comprises the following steps:
(1) each crude drug is taken by following parts by weight: Radix Ginseng Rubra 110 parts, Radix Salviae Miltiorrhizae 190 parts, Radix Notoginseng 110 parts, Eupolyphaga Seu Steleophaga 60 parts, Squama Manis 90 parts, Hirudo 60 parts, Radix Et Rhizoma Rhei 70 parts;
(2) get Radix Ginseng Rubra, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo, be ground into fine powder, for subsequent use;
(3) Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei is got, add alcohol reflux 2 times, the consumption of ethanol is: the weight of ethanol: gross weight=6 of Radix Salviae Miltiorrhizae and Radix Et Rhizoma Rhei, ethanol used to be mass percent concentration be 80% ethanol, boil at every turn and carry 1.5 hours, merge extractive liquid, filter, gained filtrate reduced in volume reclaims ethanol, and filtrate concentrating obtains the alcohol extraction clear paste that relative density is 1.25;
Alcohol extraction filtration residue adds water and decocts 2 times again, each 1.5 hours, collecting decoction, and filter, filtrate reduced in volume obtains the water extraction clear paste that relative density is 1.25;
Alcohol extraction clear paste and water extraction clear paste are merged, mixing, obtained clear paste, for subsequent use;
(4) clear paste that fine powder step (2) obtained and step (3) obtain mixes, and dries, then is ground into fine powder, make granule, incapsulate, obtain the capsule of the Chinese medicine composition being used for the treatment of apoplexy, its content is red-brown powder, gas raw meat, mildly bitter flavor.
Embodiment 3
Be used for the treatment of a Chinese medicine composition for apoplexy, be made up of the crude drug of following parts by weight:
Radix Ginseng Rubra 100 parts
Radix Salviae Miltiorrhizae 200 parts
Radix Notoginseng 100 parts
Eupolyphaga Seu Steleophaga 50 parts
Squama Manis 100 parts
Hirudo 50 parts
Radix Et Rhizoma Rhei 60 parts.
This is used for the treatment of the preparation method of the Chinese medicinal composition capsules agent of apoplexy, comprises the following steps:
(1) each crude drug is taken by following parts by weight: Radix Ginseng Rubra 100 parts, Radix Salviae Miltiorrhizae 200 parts, Radix Notoginseng 100 parts, Eupolyphaga Seu Steleophaga 50 parts, Squama Manis 100 parts, Hirudo 50 parts, Radix Et Rhizoma Rhei 60 parts;
(2) get Radix Ginseng Rubra, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo, be ground into fine powder, for subsequent use;
(3) Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei is got, add alcohol reflux 2 times, the consumption of ethanol is: the weight of ethanol: gross weight=6 of Radix Salviae Miltiorrhizae and Radix Et Rhizoma Rhei, ethanol used to be mass percent concentration be 80% ethanol, boil at every turn and carry 1.5 hours, merge extractive liquid, filter, gained filtrate reduced in volume reclaims ethanol, and filtrate concentrating obtains the alcohol extraction clear paste that relative density is 1.25;
Alcohol extraction filtration residue adds water and decocts 2 times again, each 1.5 hours, collecting decoction, and filter, filtrate reduced in volume obtains the water extraction clear paste that relative density is 1.25;
Alcohol extraction clear paste and water extraction clear paste are merged, mixing, obtained clear paste, for subsequent use;
(4) clear paste that fine powder step (2) obtained and step (3) obtain mixes, and dries, then is ground into fine powder, make granule, incapsulate, obtain the capsule of the Chinese medicine composition being used for the treatment of apoplexy, its content is red-brown powder, gas raw meat, mildly bitter flavor.
Clinical trial example
1, the impact of MCAO rat is tested
1.1 experiment material
Adopt body weight the Wistar rat of 250-350g, totally 40, be divided into two groups at random, experimental group 20, matched group 20.
1.2 Experimental agents
Experimental group: adopt the capsule that embodiment 1 is obtained, specification 0.5g × 60 × 1 box, becomes 1ml/50mg with 0.9% normal saline, namely contains effective ingredient 50mg in 1ml solution;
Matched group: control drug adopts TONGXINLUO JIAONANG, is produced by Shijiazhuang Yiling Pharmaceutical Co., Ltd, specification 0.26g × 30 × 1 box, becomes 1ml/50mg with 0.9% normal saline equally.
1.3 application dosage
Experimental group: 1g/kg/d; Matched group: 1g/kg/d.
1.4 experimental technique
1.4.1 modeling
Reference literature (Wang Shizhong, Liu Shu is clean, the discussion of evaluating focal brain ischemia in rats manufacturing technology [[J]. Medical University Of Tianjin's journal, 1999, 5 (4): 72-73) method introduced makes evaluating focal brain ischemia in rats: after anaesthetizing rats by intraperitoneal injection with 10% chloral hydrate solution 350mg/kg, rat head right arm reclining is fixed on Mus plate, local cropping, routine disinfection, adjoin outside right eye and be about 1.5cm with the mid point line longitudinal incision skin of right external auditory canal, Temporal fascia is untied along temporal bone edge, blunt separation temporalis, until expose temporo squama and the ala magna ossis sphenoidalis of temporal bone completely, above zygomatic arch, temporo squama and ala magna ossis sphenoidalis intersection are holed, sting bone downwards by vascular forceps subsequently hole is expanded, do 3x4mm bone window, cerebral dura mater is punctured with fine needle, pia mater encephali around separating blood vessel and arachnoidea tissue, make it free, then gently middle cerebral artery is provoked with fine needle at tractus olfactorius and middle cerebral artery intersection, expose middle cerebral artery proximal section, middle cerebral artery is closed with small bipolar electrocoagulator electric heating is solidifying, cause the focal cerebral ischemia in rats blocked caused by middle cerebral artery (MCAO), temporalis is resetted, sew up wound.Postoperative 2h keeps anus temperature in (37 ± 0.5) DEG C.The successful mark of model is the hemiplegia occurring seeking peace the Homer of homonymy after animal revives offside attaches most importance to forelimb.
1.4.2 30min administration after modeling success, two groups of equal gastric infusion 1g/kg.
1.5 experimental result
Normal rat uses embodiment 1 capsule 1 hour Cerebral Blood Flow Following obviously to be increased, and after medicine, 2 hours cerebral blood flows still keep higher level, later prolongation in time, and increasing degree reduces gradually, on blood pressure without impact.Matched group medicine has certain effect, but not obvious.
Specific experiment result data is in shown in Table 1-6.
The shadow noon of the total SOD activity of table 1 pair Focal Cerebral Ischemia-Reperfusion in Rats cerebral tissue
| Group | Number of animals (only) | Dosage (g/kg) | SOD activity (U/mgprot) |
| Experimental group | 20 | 1 | 159.47±17.83 |
| Matched group | 20 | 1 | 117.31±23.01 |
The shadow noon of the total MDA content of table 2 pair Focal Cerebral Ischemia-Reperfusion in Rats cerebral tissue
| Group | Number of animals (only) | Dosage (g/kg) | MDA(nmol/mgprot) |
| Experimental group | 20 | 1 | 14.49±1.82 |
| Matched group | 20 | 1 | 19.37±2.56 |
Table 3 is to the shadow noon of focal cerebral ischemia stove peripheral nerve-cell number
| Group | Number of animals (only) | Dosage (g/kg) | Neurocyte number (individual/visual field) |
| Experimental group | 20 | 1 | 124.7±39.64 |
| Matched group | 20 | 1 | 102.3±54.32 |
Table 4 is on the impact of the total glutamic acid of Focal Cerebral Ischemia-Reperfusion in Rats cerebral tissue
| Group | Number of animals (only) | Dosage (g/kg) | Glutamic acid (umol/mgprot) |
| Experimental group | 20 | 1 | 276.85±29.74 |
| Matched group | 20 | 1 | 338.91±31.79 |
The shadow noon that table 5 couple Focal Cerebral Ischemia-Reperfusion in Rats cerebral tissue LPO generates
| Group | Number of animals (only) | Dosage (g/kg) | LOP content (OD value) |
| Experimental group | 20 | 1 | 0.518±0.071 |
| Matched group | 20 | 1 | 0.679±0.077 |
The shadow noon of neural factor NGF in table 6 pair brain of rat with focal cerebral ischemia reperfusion
As can be seen from table 1-6 data, embodiment 1 capsule is compared with TONGXINLUO JIAONANG, the capsule that embodiment 1 obtains makes neural factor NGF in SOD activity, peripheral nerve-cell number, brain significantly improve, MDA, glutamic acid, LOP obviously reduce, and P < 0.05, possess significant statistical significance.
Improve the activity of cerebral tissue SOD, oxygen radical removing effect can be strengthened, reduce the amino acid residue oxidation reaction of free radical and protein, alleviate the toxicity of oxygen-derived free radicals during cerebral ischemia; Neurologic defect symptom can be improved, to rats with cerebral ischemia, there is neuroprotective.After cerebral ischemia; NGF expresses increase; have and improve Neuronal Survival rate and promote the activity that neurocyte extends; but it is very short that the expression of endogenous NGF increases time-histories; expression is limited; in addition the neuron that damage location is a large amount of is vied each other NGF, is therefore difficult to have comprehensive and lasting protective effect to ischemic brain area injured neurons.Therefore, after modeling 2h hour, test group administration in 30min, improves the expression of NGF in early stage Mus cerebral ischemia hindbrain, is significant to neuranagenesis and functional rehabilitation.
2, the clinical observation on the therapeutic effect experiment of Ischemic Apoplexy Patients is treated
2.1 experimental subject
Adopt the capsule that embodiment 2 is obtained, treat 300 routine patients altogether, wherein man 180 example, female 120 example, the oldest 87 years old, age reckling 21 years old.
2.2 drug usage consumptions
Oral, each 4, every day three times 15 days is a course for the treatment of, takes 5-6 the course for the treatment of continuously.
2.3 the standard of curative effect evaluation
Adopt " apoplexy diagnosis and efficacy assessment standard " (secondary standard), worked out by State Scientific and Technological Commission's brainstorm project " research of 85-919-02-01 apoplexy syndrome manifestations and clinical diagnosis " seminar, State Administration of Traditional Chinese Medicine's encephalopathy emergency case scientific research cooperative groups.
(1) diagnostic criteria of apoplexy class is specific as follows:
1. god knows
2. language
3. facial paralysis
Without 0 point
Paresis 1 point
Panplegia 2 points
4. eye is levied
Without 0 point
Two orders hang oneself 2 points
Order inclined not wink 4 points
5. paralysis of upper extremities
6. paralysis is referred to
7. lower limb paralysis
8. toe paralysis
9. other diseases are levied
Methods of marking: diagnostic score is that the addition of every best result forms, and full marks are 52 points.
Diagnostic classification: 1 ~ 13 point, for light-duty;
14 ~ 26 points is plain edition;
27 ~ 39 points is heavy type;
More than 40 points is extremely heavy.
(2) apoplexy efficacy assessment standard
1. efficacy evaluation explanation
Scoring and percent Commutation Law of marking after treating before treatment
[before (before treatment the rear integration of integration-treatment) ÷ treatment integration] × 100%, is expressed as a percentage.
2. efficacy assessment standard:
Basic recovery: >=81%, less than 6 points
Marked improvement: 56% ~ 80%
Progressive: 36% ~ 55%
Slightly progress: 11% ~ 35%
Unchanged: < 11%
Worsen: (comprising death) negative value.
2.4 experimental result
In 300 routine cases for the treatment of, through treatment in 3 months, wherein substantially recover 157 examples, marked improvement 93 example, progressive 32 examples, slightly progressive 18 examples, unchanged 0 example, worsen 0 example, total effective rate reaches 100%.Experimental result shows, the capsule that embodiment 2 obtains has the curative effect of highly significant to treatment cerebral infarction.
Model case
1, Liu so-and-so, man, 83 years old, is chief complaint is admitted to hospital with " movable unfavorable 20 years of left lower extremity increases the weight of companion dizzy 1 week ".When being admitted to hospital, disease is seen: left lower extremity muscular strength II grade, hypermyotonia, dizzy, weak, the slurred speech in the whole body.Look into cerebral CT to show: Multiple Brain blocks.Take embodiment 1 capsule after 3 months, dizziness is strong without, body sense, and speech is slightly clear, left lower extremity muscular strength IV grade, and muscular tension declines.Efficacy assessment standard >=90%, recovers substantially.
2, Zhang, man, 27 years old, is chief complaint is admitted to hospital with " burst is fainted two hours ".When being admitted to hospital, disease is seen: extremity muscular strength III grade, hypermyotonia, confusion, answer undercurrent profit.Suddenly look into cerebral CT to show: right side thalamus, left side occipital lobe cerebral infarction.Take embodiment 2 capsule after 3 months, extremity muscular strength IV grade, muscular tension obviously declines, Consciousness, and it is fluent to answer.Efficacy assessment standard >=89%, recovers substantially.
3, Lin, female, 69 years old, is chief complaint is admitted to hospital with " unfavorable 5 years of right side limb activity increases the weight of companion's distortion of commissure 5 days ".When being admitted to hospital, disease is seen: right side myodynamia II grade, hypermyotonia, and bicker is crooked, right side blepharoptosis to the left, right side disapperance of nasolabial sulcus.Take embodiment 3 capsule after 3 months, extremity muscular strength IV grade, muscular tension decline, distortion of commissure without.Efficacy assessment standard >=92%, recovers substantially.
4, fourth, man, 50 years old, is chief complaint is admitted to hospital with " numb 1 week of left limb ".When being admitted to hospital, disease is seen: left side muscular strength IV grade, and hypermyotonia, left limb are numb, movable unfavorable.Look into cerebral CT to show: basal ganglia region, left side cerebral infarction.Take embodiment 3 capsule after 3 months, extremity muscular strength V grade, muscular tension is normal, and left limb numbness is without, freedom of movement.Efficacy assessment standard >=95%, recovers substantially.
5, grandson so-and-so, female, 42 years old, is chief complaint is admitted to hospital with " dizzy dizzy companion slurred speech 1 day 3 times ".When being now admitted to hospital, disease is seen: two lower-limb muscular strength IV grade, and muscular tension slightly increases, dizzy giddy, slurred speech, two numbness of lower limbs, activity are unfavorable.Look into cerebral CT to show: bilateral occipital lobe, frontal lobe, basal ganglia region lacunar infarction.Take embodiment 1 capsule after 3 months, extremity muscular strength V grade, muscular tension is normal, dizzy without, two numbness of lower limbs without, freedom of movement.Efficacy assessment standard >=93%, recovers substantially.
Claims (5)
1. be used for the treatment of a Chinese medicine composition for apoplexy, it is characterized in that, be made up of the crude drug of following parts by weight:
2. the Chinese medicine composition being used for the treatment of apoplexy according to claim 1, is characterized in that, described Chinese medicine composition is capsule or tablet or granule.
3. be used for the treatment of a preparation method for the Chinese medicine composition of apoplexy, it is characterized in that, comprise the following steps:
(1) each crude drug is taken by following parts by weight: Radix Ginseng Rubra 90-110 part, Radix Salviae Miltiorrhizae 190-210 part, Radix Notoginseng 90-110 part, Eupolyphaga Seu Steleophaga 40-60 part, Squama Manis 90-110 part, Hirudo 40-60 part, Radix Et Rhizoma Rhei 50-70 part;
(2) get Radix Ginseng Rubra, Radix Notoginseng, Eupolyphaga Seu Steleophaga, Squama Manis, Hirudo, be ground into fine powder, for subsequent use;
(3) get Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, add alcohol reflux 2 times, boil at every turn and carry 1.5 hours, merge extractive liquid, filter, gained filtrate reduced in volume reclaims ethanol, and filtrate concentrating obtains the alcohol extraction clear paste that relative density is 1.25;
Alcohol extraction filtration residue adds water and decocts 2 times again, each 1.5 hours, collecting decoction, and filter, filtrate reduced in volume obtains the water extraction clear paste that relative density is 1.25;
Described alcohol extraction clear paste and described water extraction clear paste are merged, mixing, obtained clear paste, for subsequent use;
(4) clear paste that fine powder step (2) obtained and step (3) obtain mixes, and dries, then is ground into fine powder, make granule, incapsulate, obtain the Chinese medicine composition being used for the treatment of apoplexy.
4. the preparation method being used for the treatment of the Chinese medicine composition of apoplexy according to claim 3, is characterized in that, in step (3), when adding alcohol reflux, the consumption of ethanol is: the weight of ethanol: gross weight=6 of Radix Salviae Miltiorrhizae and Radix Et Rhizoma Rhei.
5. the preparation method being used for the treatment of the Chinese medicine composition of apoplexy according to claim 3 or 4, is characterized in that, in step (3), when adding alcohol reflux, ethanol used to be mass percent concentration be 80% ethanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410853808.4A CN104523861A (en) | 2014-12-31 | 2014-12-31 | Traditional Chinese medicine combination used for treating stroke and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410853808.4A CN104523861A (en) | 2014-12-31 | 2014-12-31 | Traditional Chinese medicine combination used for treating stroke and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104523861A true CN104523861A (en) | 2015-04-22 |
Family
ID=52839617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410853808.4A Pending CN104523861A (en) | 2014-12-31 | 2014-12-31 | Traditional Chinese medicine combination used for treating stroke and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104523861A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362740A (en) * | 2015-11-16 | 2016-03-02 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treatment of stroke and application thereof |
| CN106880732A (en) * | 2017-02-17 | 2017-06-23 | 成都风靡生物科技有限公司 | It is a kind of to treat capsule medicine of apoplexy and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019926A (en) * | 2007-02-13 | 2007-08-22 | 张宗保 | Chinese medicine for treating cardiac and cerebral vascular diseases and its prepn process |
| CN102423328A (en) * | 2011-09-15 | 2012-04-25 | 北京建生药业有限公司 | Traditional Chinese medicine composition for treating cerebral apoplexy and its preparation method |
-
2014
- 2014-12-31 CN CN201410853808.4A patent/CN104523861A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019926A (en) * | 2007-02-13 | 2007-08-22 | 张宗保 | Chinese medicine for treating cardiac and cerebral vascular diseases and its prepn process |
| CN102423328A (en) * | 2011-09-15 | 2012-04-25 | 北京建生药业有限公司 | Traditional Chinese medicine composition for treating cerebral apoplexy and its preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 胡艮贵: "蛭蝎粉用于脑血管意外恢复期疗效观察", 《实用中医药杂志》 * |
| 董少龙: "中风病临床治疗体会", 《现代中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362740A (en) * | 2015-11-16 | 2016-03-02 | 宁国仙霞骨伤医院 | Traditional Chinese medicine composition for treatment of stroke and application thereof |
| CN106880732A (en) * | 2017-02-17 | 2017-06-23 | 成都风靡生物科技有限公司 | It is a kind of to treat capsule medicine of apoplexy and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104147284B (en) | Chinese herbal preparation for treating epilepsy and preparation method thereof | |
| CN101129973A (en) | Traditional Chinese medicine for treating cervical vertebra disease | |
| CN1628760A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN100579556C (en) | Preparation method of Chinese medicinal capsule for treating apoplexy | |
| CN1853679A (en) | Medicinal composition for treating cervical spondylosis and preparation thereof | |
| CN1994411A (en) | Medicine for treating cerebral apoplexy | |
| CN100482257C (en) | Zuanshanfeng wind damp oil and its preparation method | |
| CN104523861A (en) | Traditional Chinese medicine combination used for treating stroke and preparation method thereof | |
| CN1235630C (en) | Chinese medicine paste for curing osteoarthropathy and preparing method | |
| CN102885983A (en) | Chinese medicinal composition for treating stroke | |
| CN105106440A (en) | Traditional Chinese medicine composition for treating headache and dizziness induced by lumbar anesthesia | |
| CN104784398B (en) | The external-applied ointment and preparation method thereof for treating apoplexy sequelae | |
| CN1709458A (en) | Medicine for treating coronary clisease | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN104524397A (en) | Traditional Chinese medicine composition for assisted rehabilitation of stroke and preparation method of composition | |
| CN101129425A (en) | Traditional Chinese medicine for treating zoster | |
| CN104147174A (en) | Medicament for treating stroke | |
| CN114504635B (en) | Chinese patent medicine for treating apoplexy sequela | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN115177690B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN102319330A (en) | Traditional Chinese medicine cataplasma for treating hyperosteogeny and preparation method thereof | |
| CN101637535B (en) | Medicine for treating bone hyperplasia and preparation method thereof | |
| CN105106855A (en) | Traditional Chinese medicine preparation for treating apoplexy sequela | |
| CN105106786A (en) | Traditional Chinese medicine composition capable of dredging collaterals and relaxing muscles as well as preparation and production method of composition | |
| CN1698727A (en) | Mightiness pulse invigorating capsule and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |